secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vistagen Therapeutics, Inc. (VTGN)
CIK:        0001411685
Form:       8-K
Filed at:   2025-01-14T23:59:59+00:00
Accession:  0001411685-25-000007
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vistagen announces positive Phase 2A results for PH284 in cancer cachexia; 71% hunger improvement
--------------------------------------------------------------------------------

- PH284 nasal spray demonstrated 71% improvement in subjective feeling of hunger before dinner on Day 7 vs <1% for placebo.
- No serious adverse events; adverse events similar to placebo and attributed to underlying cancer, not treatment.
- PH284 is fifth pherine product candidate in Vistagen's neuroscience pipeline with a positive efficacy signal.
- Study enrolled 40 female patients with cachexia due to terminal cancer; double-blind, placebo-controlled design.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1411685/000141168525000007/0001411685-25-000007-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1411685/000141168525000007/vtgn-20250114.htm
  HTML page:      https://secwatch.observer/filing/0001411685-25-000007

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer